CN103565740A - Loteprednol etabonate suspension eye drops - Google Patents
Loteprednol etabonate suspension eye drops Download PDFInfo
- Publication number
- CN103565740A CN103565740A CN201210259749.9A CN201210259749A CN103565740A CN 103565740 A CN103565740 A CN 103565740A CN 201210259749 A CN201210259749 A CN 201210259749A CN 103565740 A CN103565740 A CN 103565740A
- Authority
- CN
- China
- Prior art keywords
- eye drop
- suspendible
- loteprednol etabonate
- suspendible eye
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 76
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 title claims abstract description 49
- 229960003744 loteprednol etabonate Drugs 0.000 title claims abstract description 48
- 239000000725 suspension Substances 0.000 title abstract description 16
- 229940012356 eye drops Drugs 0.000 title abstract description 7
- 239000002245 particle Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000009826 distribution Methods 0.000 claims abstract description 8
- -1 antibacterial Substances 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 8
- 229960004224 tyloxapol Drugs 0.000 claims description 8
- 229920001664 tyloxapol Polymers 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000375 suspending agent Substances 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 17
- 239000000463 material Substances 0.000 abstract description 10
- 239000003814 drug Substances 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 239000007788 liquid Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 9
- 238000012856 packing Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 229960000707 tobramycin Drugs 0.000 description 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003923 gatifloxacin Drugs 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- XUBOMFCQGDBHNK-UHFFFAOYSA-N gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses loteprednol etabonate suspension eye drops. The loteprednol etabonate suspension eye drops contain loteprednol etabonate as an active component, water and one or more accessory materials for suspension eye drops. The used loteprednol etabonate micro-powder meets the particle size distribution conditions comprising that D50 is in a range of 3.0-4.0 microns, the maximum particle size is less than 30 microns, a ratio of micro-powder particles having sizes of 1-8 microns is in a range of 79-85%, and a ratio of micro-powder particles having sizes of 1-4 microns is in a range of 49-56%.
Description
Technical field:
The present invention relates to a kind of glucocorticoid eye suspendible eye drop.
Background technology:
Loteprednol etabonate (CAS:82034-46-6, Loteprednol etabonate), it is a kind of novel glucocorticoid, owing to having it, to rise ocular hypertensive side effect less, therefore for the preparation of ophthalmic preparation, existing ophthalmic preparation has the Loteprednol etabonate suspendible eye drop (trade name: Lu Dashu) of Bausch & Lomb Incorporated production.US Patent No. 5540930 and US5747061A disclose a kind of Loteprednol etabonate suspensoid that eye is used, nose is used that is applicable to, and all disclosing the Loteprednol etabonate grain size of micropowder scope adopting is 0.1-30 μ m, but unexposed particle size distribution more specifically.(Yu Qingzhen, Shanghai medicine the 20th volume o. 11th in 1999 disclose particle size range and the distribution as the dexamethasone drug powder of active component in 36-37) to China's document " development of compound tobramycin suspendible eye drop ".Wherein approach the micropowder that 99% drug particles is 1-5 μ m, we find, the suspensoid of preparing according to this diameter of aspirin particle scope, no doubt can meet national standard, but due to adding of the adjuvants such as suspending agent, liquid viscosity is increased, make to obtain suspension after drug particles precipitates completely, need the jolting of long period can realize sufficient redispersion, in Chinese Pharmacopoeia, eye is not made stipulations by the redispersibility of suspensoid, China's document " the suspending agent screening of acyclovir ophthalmic suspension " (Liu Jie etc., food and pharmaceutical the 10th volume o. 11th in 2008, a kind of detection method of redispersibility is disclosed 21-23), by adopting the nessler colorimetric tube upset of 25ml to mix, detect the redispersibility that average upset number of times characterizes suspensoid, but in fact, after unpacking, place and pollute for a long time, the packing specification of eye drop is generally no more than 5ml, and different from the glass material of color comparison tube, eye-drop liquid bottle is generally the plastic materials such as PET/PE/PP, the tension force of its inner surface and imbibition characteristic and glass material also exist obvious difference, in fact through us, test discovery, adopt suspension and conventional 25ml or the glass material color comparison tube of 50ml of conventional plastic bottle fractional pack, when redispersibility is tested, show characteristic inconsistent.Performance bad when some suspension of doing well in conventional redispersibility test adopts fractional pack to test again.In addition, a lot of user are when being used suspendible eye drop, often adopt jolting form to carry out redispersion, and jolting or upset number of times are generally all less, also different with the upset in common test, and, a lot of user are when drug development, development person often ignores this point, therefore the suspension of preparing, it all cannot realize sufficient redispersion in a lot of actual situations about using, thereby cause and splash into dosage and nominal standard dose is not inconsistent, especially along with the use of medicine, to the later stage, drug level and labelled amount produce larger difference, thereby will directly affect therapeutic effect.
Summary of the invention:
By test, the discovery that we are surprised, when selecting the active component micropowder of specific particle size distribution, resulting Loteprednol etabonate suspendible eye drop, when meeting suspensoid quality standard, through jolting for several times, just can be realized sufficient redispersion.Solved existing suspendible eye drop causes the drug level that splashes in eye and nominal value not to be inconsistent problem because redispersibility is bad.
The percentage ratio that relates to grain size of micropowder scope in description of the present invention and embodiment is particulate percentages, and the micro powder granule number in certain particle size range accounts for the percentage ratio of total particle number.Generally take laser particle analyzer to detect.
The particle diameter of indication of the present invention is D50 particle diameter, corresponding particle diameter when the cumulative particle sizes distribution number of a sample reaches 50%.Its physical significance be particle diameter be less than it granule number account for 50% of total amount.
The invention provides a kind of Loteprednol etabonate suspendible eye drop, contain the Loteprednol etabonate as active component, water is applicable to the adjuvant of suspendible eye drop with one or more, it is characterized in that, described Loteprednol etabonate micropowder, its particle size distribution meets the following conditions simultaneously:
D50 is 3.0-4.0 μ m, and maximum particle diameter is less than 30 μ m,
Particle diameter is at the micropowder of 1-8 μ m, and particulate percentages is 79%-85%, wherein
Particle diameter is at the micropowder of 1-4 μ m, and particulate percentages is 49%-56%.
Described suspendible eye drop, the bulking value percentage composition that it is characterized in that Loteprednol etabonate is 0.1%-2%.Preferred 0.2%-1%.
Described suspendible eye drop, it is characterized in that containing one or more eye medicinals, described eye medicinal is selected from one or more in hyaluronic acid or its salt, antibiotic, described antibiotic is selected from a kind of in quinolones, fluoroquinolones, aminoglycoside antibiotics, preferably a kind of in tobramycin, gentamycin, Gatifloxacin, ofloxacin, levofloxacin or its salt.
Described suspendible eye drop, the described adjuvant that is applicable to suspendible eye drop is selected from one or more in pH adjusting agent, osmotic pressure regulator, suspending agent, antioxidant, chelating agen, surfactant.
Described pH adjusting agent is selected from one or more in phosphoric acid and salt, boric acid and salt thereof, citric acid and salt thereof, acetic acid and salt thereof, tartaric acid and salt thereof, sulphuric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, tromethane.
Described osmotic pressure regulator is selected from glycerol, propylene glycol, sodium chloride, potassium chloride, Sorbitol, mannitol.One or more in preferred sodium chloride, glycerol, propylene glycol.
Described antibacterial is selected from one or more in benzalkonium chloride, benzethonium chloride, sorbic acid, potassium sorbate, benzyl alcohol, methyl parahydroxybenzoate (methyl hydroxybenzoate), propyl p-hydroxybenzoate (propylparaben), chlorobutanol.
Described suspending agent is selected from one or more in sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, polyvinyl alcohol, carboxy vinyl polymer, polyvinyl pyrrolidone, carbomer.One or more in preferred carbomer, hydroxypropyl emthylcellulose, methylcellulose, hydroxyethyl-cellulose, polyvinyl pyrrolidone.
Described surfactant is selected from tween 80, polyoxyethylene castor oil 60, HCO60, polyglycol distearate, Polyethylene Glycol, lecithin, sucrose ester, polyoxyethylene aliphatic alcohol ether, one or more in poloxamer, tyloxapol (Tyloxapol), preferably one or more in tween 80, HCO60, polyoxyethylene castor oil 60, tyloxapol (Tyloxapol).
Described chelating agen is selected from disodium edetate or calcium disodium edetate.
Described antioxidant can be selected from one or more in sodium sulfite, sodium sulfite, sodium pyrosulfite.
Loteprednol etabonate suspendible eye drop preferably, is characterized in that the component that the described adjuvant that is applicable to suspendible eye drop contains following percent weight in volume:
Glycerol and/or propylene glycol, 1%-5%,
Tyloxapol, 0.1%-1%,
PVP K30,0.2%-1%.
Preferably also contain
Disodium edetate or calcium disodium edetate, 0.01%-0.1%,
Antibacterial, 0.01%-0.1%.
Described percent weight in volume is the percentage ratio of composition weight and suspendible eye drop volume.
The preparation method that a kind of Loteprednol etabonate micropowder is provided of the present invention, it is characterized in that, Loteprednol etabonate is dissolved in the organic solvent dissolving each other with water, separately getting water for injection stirs, stir on limit, limit slowly splashes into the organic solvent solution of Loteprednol etabonate, all splashes into rear lasting stirring 15-30min.Filtration obtains Loteprednol etabonate micropowder.
The preparation method of described Loteprednol etabonate micropowder, one or more in the preferred lower alcohol of organic solvent, acetone, oxolane, described lower alcohol is the monohydric alcohol of C1-C4, the envelope-bulk to weight ratio of described organic solvent and Loteprednol etabonate is preferably 1:10-20, preferably by the organic solvent that has dissolved Loteprednol etabonate filtering with microporous membrane degerming.The volume ratio of described water for injection and organic solvent is preferably 5-10:1.
Institute of the present invention defined particle size scope is for adopting laser particle analyzer to detect the data that obtain.
A kind of suspendible eye drop provided by the invention, compare with suspendible eye drop of the prior art, in standing storage a period of time, in situation at the bottom of drug powder has been deposited to bottle completely, all after 5-6 jolting or upset, can realize very soon redispersion, and suspendible eye drop prepared by the micropowder that adopts existing particle size range, although testing with suspendible eye drop provided by the invention, its settling ratio and the redispersion that adopts 25ml glass color comparison tube to carry out there is no significant difference, but when suspendible eye drop is distributed into after plastic bottle fractional pack, in the upset experiment 2 and jolting experiment that are more similar to actual service condition, eye drop provided by the invention, show better redispersion characteristic, the upset of number of times still less and and jolting under can realize sufficient redispersion, the eye drop that redispersion Temin is aobvious is better than adopting the drug powder of existing particle size range to be prepared, illustrate that the present invention is by the particle size range of preferred Loteprednol etabonate micropowder, obtain a kind of which kind of mode that no matter adopts and can realize very soon redispersion, and with the better suspendible eye drop of the eye-drop liquid bottle suitability of plastic bottle material, by the later stage uniformity, test simultaneously, more show, the eye drop Loteprednol etabonate eye drop provided by the invention of preparing with existing particle size range drug powder is because its redispersibility is better, between the whole operating period, can keep higher uniformity of dosage units, effective ingredient concentration is substantially with using the consumption of eye drop to change.
The specific embodiment
Adopt Hydro 2000MU type laser particle analyzer.
Following embodiment calculates inventory according to every 1000ml suspension, and the accessory formula of all suspendible eye drops is as follows,
The Loteprednol etabonate micropowder preparation method formula of embodiment 1 ~ embodiment 15 sees the following form, wherein
Solvent A is oxolane; Solvent B is ethanol; Solvent C is methanol; Solvent D is acetone
Ratio 1 represents the envelope-bulk to weight ratio of organic solvent and Loteprednol etabonate
Ratio 2 is the volume ratio of solvent and water
In embodiment 2, component 2 is tobramycin, and in embodiment 6, component 2 is levofloxacin hydrochloride, and in embodiment 10, component 2 is GATIFLOXACIN.
Described Loteprednol etabonate micropowder preparation method is: medicine material is dissolved into (heating if desired) in organic solvent, cross 0.45 μ m microporous filter membrane, getting water for injection stirs, maintaining under stirring condition, speed with 0.5-1ml/s slowly drips the organic solvent that has dissolved medicine in water, after finishing, stop stirring, within standing 1 hour, filtration drying obtains drug powder.Described drug powder particle size distribution meets following condition simultaneously:
D50 is 3.0-4.0 μ m, and maximum particle diameter is less than 30 μ m,
Particle diameter is at the micropowder of 1-8 μ m, and particulate percentages is 79%-85%, wherein
Particle diameter is at the micropowder of 1-4 μ m, and particulate percentages is 49%-56%.
Compound method:
The adjuvant of recipe quantity and water-soluble medicine (are only limited to embodiment 2, 6, 10) be dissolved in the water of recipe quantity 90%, after fully dissolving, obtain liquid <1>, take out 10% of liquid <1>, drug powder is added wherein and stirs and make dense thick suspension, again dense thick suspension is added in raffinate <1>, stir and supply water for injection to recipe quantity, obtain target suspension, specification described in table on suspension is distributed into 2ml or the bottled eye drop of 5ml.Standby.
Embodiment 1-3 eye-drop liquid bottle adopts PET(polyethylene terephthalate) material, embodiment 4-7 eye-drop liquid bottle adopts PP(polypropylene) material, and embodiment 7-10 eye-drop liquid bottle adopts PE(polyethylene) material
Embodiment 1
Accessory formula is hydroxypropyl emthylcellulose 10g
Tween 80 0.5g
HCO60 0.5g
Propylparaben 0.5g
Methyl hydroxybenzoate 0.5g
Calcium disodium edetate 1g
Sodium chloride 7g
Water for injection is to 1000ml
Embodiment 2
Accessory formula is hydroxyethylmethyl-cellulose 20g
Tween 80 0.5g
Glycerol 10g
Hyaluronate sodium 1g
HCO60 0.5g
Benzalkonium chloride
Calcium disodium edetate 1g
Water for injection is to 1000ml
When preparation to after adding tobramycin in liquid <1> with sulfur acid for adjusting pH to 5-6.
Embodiment 3.-8 accessory formula see the following form (in 1000ml suspension)
Embodiment 9
Accessory formula is methylcellulose 20g
Tween 80 3g
Propylparaben 0.5g
Methyl hydroxybenzoate 0.5g
Calcium disodium edetate 1g
Sodium chloride 7g
Water for injection is to 1000ml
Embodiment 10
Accessory formula is hydroxypropyl emthylcellulose 50g
Tween 80 0.5g
Glycerol 10g
Polyoxyethylene castor oil 60 0.5g
Benzalkonium chloride
Calcium disodium edetate 1g
Water for injection is to 1000ml
Reference examples 1-1-reference examples 10-1
According to the formula of embodiment 1-embodiment 10, adopt fluid energy mill to pulverize respectively and obtain Loteprednol etabonate micropowder, gained drug powder mean diameter is 10 μ m, and maximum particle diameter is less than 30 μ m, and the eye drop that packing obtains is routine 1-1 ~ reference examples 10-1 in contrast.
Reference examples 1-2-reference examples 10-2
According to the formula of embodiment 1-embodiment 10, adopt fluid energy mill to pulverize respectively and obtain Loteprednol etabonate micropowder, gained drug powder maximum particle diameter is less than 20 μ m, between 90% drug powder particle diameter 1-3 μ m, the eye drop that packing obtains is routine 1-1 ~ reference examples 10-2 in contrast.
EXPERIMENTAL EXAMPLE again distributes
Settling volume is than detecting
According to the detection method of disclosed suspendible eye drop in 2010 editions appendix 10 of Chinese Pharmacopoeia, detect embodiment 1-embodiment 10, reference examples 1-1 ~ reference examples 10-1, and reference examples 1-2 ~ reference examples 10-2 makes the settling ratio H of suspendible eye drop.Through detecting the settling ratio of all samples, be all greater than 0.90, meet the requirement in Chinese Pharmacopoeia 2010 editions.
Upset experiment 1 turns at vertical plane internal rotation around its center of gravity
To test drugs packaging in 25 mL nessler colorimetric tubes, after the static placement of room temperature 2d, spin upside down color comparison tube to bottom without precipitation, in suspension without grumeleuse.In experiment, every upset once refers to and will test medicine be housed, and original state is that mouth of pipe color comparison tube straight up planar carries out dextrorotation turnback to the opposite direction of the mouth of pipe towards original sensing at major axis, and reversal rate is upset per second 2 times.The average upset of record number of times.The results are shown in following table, n=5
| Embodiment numbering | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Average upset number of times | 2.6 | 2.4 | 2.4 | 2.6 | 2.4 | 2.6 | 2.6 | 2.4 | 2.6 | 2.4 |
| Reference examples numbering | 1-1 | 2-1 | 3-1 | 4-1 | 5-1 | 6-1 | 7-1 | 8-1 | 9-1 | 10-1 |
| Average upset number of times | 2.4 | 2.4 | 2.6 | 2.4 | 2.6 | 2.6 | 2.6 | 2.4 | 2.6 | 2.4 |
| Reference examples numbering | 1-2 | 2-2 | 3-2 | 4-2 | 5-2 | 6-2 | 7-2 | 8-2 | 9-2 | 10-2 |
| Average upset number of times | 2.4 | 2.6 | 2.6 | 2.4 | 2.4 | 2.4 | 2.4 | 2.6 | 2.4 | 2.4 |
When upset experiment 1 shows to adopt 25ml nessler colorimetric tube as experimental facilities, the sample redispersion characteristic of all embodiment and reference examples is basically identical without significant difference.
Upset experiment 2
Adopt and divided the embodiment 1-embodiment 10 installing, reference examples 1-1 ~ reference examples 10-1, and reference examples 1-2 ~ reference examples 10-2, after standing 2d, every group samples 10 bottles, overturn after 6 times, from bottleneck sampling, from upper strata sampling 0.1ml, survey the wherein concentration of Loteprednol etabonate and the ratio of nominal value immediately, and carry out experimental result and see the following form, the check of t in groups of Data Processing in Experiment employing SAS system (
)
Upset experiment 2 shows, Loteprednol etabonate suspendible eye drop provided by the invention, and after being distributed into the packing of the following specification of 5ml, after the experiment of overturning, its Loteprednol etabonate content and nominal value recording from bottleneck sampling is basically identical.And suspendible eye drop prepared by the drug powder that adopts other particle size range, the Loteprednol etabonate content and the nominal value that from bottleneck sampling, record exist obvious gap (P < 0.05).Illustrate in fact, the redispersion characteristic of the suspendible eye drop that adopts larger packing and fractional pack when overturning experiment is also inconsistent, and the present invention is by the particle size range of preferred Loteprednol etabonate, the better Loteprednol etabonate suspendible of redispersion characteristic eye drop when a kind of employing fractional pack is provided.
Jolting experiment 1
Loteprednol etabonate suspendible eye drop after the packing that the employing embodiment of the present invention and reference examples provide, method of testing is: forearm stretches out parallel with horizontal plane, hand-held medicine bottle, bottleneck vertically upward, be take ancon as axle, and in vertical guide, 90 °, fast rotational forearm is extremely vertical with horizontal plane, now bottleneck direction is parallel with horizontal plane, then fast forearm is being rotated to original position, completing this process and be jolting once, each jolting activity should complete in 1s.
Adopt and divided the embodiment 1-embodiment 10 installing, reference examples 1-1 ~ reference examples 10-1, and reference examples 1-2 ~ reference examples 10-2, after standing 2d, every group samples 10 bottles, after jolting 5 times, bottleneck sampling, from upper strata sampling 0.1ml, surveys the wherein concentration of Loteprednol etabonate and the ratio of nominal value, and carry out experimental result and see the following form, the check of t in groups of Data Processing in Experiment employing SAS system (
)
Jolting experiment shows, Loteprednol etabonate suspendible eye drop provided by the invention, and after being distributed into the packing of the following specification of 5ml, after carrying out jolting experiment, content and the nominal value of its Loteprednol etabonate medicine recording from bottleneck sampling are basically identical.And suspendible eye drop prepared by the drug powder that adopts other particle size range, content and the nominal value of the Loteprednol etabonate recording from bottleneck sampling exist obvious gap (P < 0.05), and with in upset experiment, record Loteprednol etabonate content and compare also on the low side, illustrate in fact, the redispersion characteristic of the suspendible eye drop that adopts larger packing and fractional pack when carrying out jolting experiment is also inconsistent, compare with the redispersion form of employing upset, the suspendible eye drop providing in prior art, more be not suitable for the redispersion mode that adopts jolting.
Later stage uniformity testing
Get embodiment 1 ~ embodiment 10, reference examples 1-1 ~ reference examples 10-1, and reference examples 1-2 ~ reference examples 10-2 makes each 10 bottles of suspendible eye drops.Every day, level was overturn 2 times according to method in upset experiment 2 after shaking 2 times immediately, ooze 10% of eye drop at once, all the other time eye drops are uprightly placed, within the 10th day, measure the concentration of Loteprednol etabonate and the ratio of nominal value of eye drop, described level concussion method of testing is once: forearm stretches out parallel with horizontal plane, hand-held eye drop medicine bottle, take ancon as axle, in horizontal plane, fast rotational forearm is 90 °, keep bottleneck vertically upward, and then fast forearm is rotated to original position, each jolting activity should complete in 1s.Experimental result sees the following form, the check of t in groups of Data Processing in Experiment employing SAS system (
)
Prove by experiment, adopt the suspendible eye drop of different-grain diameter drug powder, in continuing use procedure, using later stage Loteprednol etabonate content to have larger difference, the suspendible eye drop that the embodiment of the present invention provides, even adopt aforementioned number of times less, more inviolent concussion and flipped form are carried out redispersion, between the whole operating period, to the last also can also keep the homogeneity of content, embodied good redispersion characteristic, and suspension in reference examples is when adopting same upset or concussion form, redispersibility is just poor, using the concentration of later stage medicinal liquid that significant variation has occurred.
By above-mentioned experiment, can prove, the suspendible eye drop of conventional particle diameter can in use can cause initial eye drip medicament contg low, to using, later stage eye drip medicament contg is high, front and back gap is greatly about 10% left and right, the starting stage of especially using at eye drop needs most the stage of medicine often, and at this moment conventional suspendible eye drop often content is lower, cause the medicine deficiency that tells on, and the main cause that eye drop is used the higher untoward reaction often of the stage drug level in later stage to produce.In the present invention, by preferable particle size, the generation of the problems referred to above will better be avoided.
Claims (10)
1. a Loteprednol etabonate suspendible eye drop, contains as active component, and water and one or more are applicable to the adjuvant of suspendible eye drop, it is characterized in that, and described Loteprednol etabonate micropowder, its particle size distribution meets the following conditions simultaneously:
D50 is 3.0-4.0 μ m, and maximum particle diameter is less than 30 μ m,
Particle diameter is at the micropowder of 1-8 μ m, and particulate percentages is 79%-85%, wherein
Particle diameter is at the micropowder of 1-4 μ m, and particulate percentages is 49%-56%.
2. suspendible eye drop as claimed in claim 1, the bulking value percentage composition of its feature Loteprednol etabonate is 0.1%-2%.
3. suspendible eye drop as claimed in claim 1, is characterized in that containing one or more eye medicinals.
4. suspendible eye drop as claimed in claim 3, is characterized in that described eye medicinal is selected from one or more in hyaluronic acid or its salt, antibiotic.
5. the suspendible eye drop as described in as arbitrary in claim 1-4, is characterized in that the adjuvant of described suspendible eye drop is selected from one or more in pH adjusting agent, osmotic pressure regulator, suspending agent, antibacterial, antioxidant, chelating agen, surfactant.
6. suspendible eye drop as claimed in claim 10, is characterized in that described pH adjusting agent is selected from one or more in phosphoric acid and salt, boric acid and salt thereof, citric acid and salt thereof, acetic acid and salt thereof, tartaric acid and salt thereof, sulphuric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, tromethane.
7. suspendible eye drop as claimed in claim 10, is characterized in that described osmotic pressure regulator is selected from one or more in glycerol, propylene glycol, sodium chloride, potassium chloride, Sorbitol, mannitol.
8. suspendible eye drop as claimed in claim 10, is characterized in that described suspending agent is selected from one or more in sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, polyvinyl alcohol, carboxy vinyl polymer, polyvinyl pyrrolidone, carbomer.
9. suspendible eye drop as claimed in claim 10, it is characterized in that described surfactant is selected from tween 80, polyoxyethylene castor oil 60, HCO60, Polyethylene Glycol-stearate, Polyethylene Glycol, lecithin, sucrose ester, polyoxyethylene alkyl ether, polyoxy stearate, polyoxyethylene one polyoxypropylene diols, tyloxapol (Tyloxapol).
10. suspendible eye drop as claimed in claim 1., it is characterized in that the component that the described adjuvant that is applicable to suspendible eye drop contains following percent weight in volume: glycerol and/or propylene glycol, 1%-5%, tyloxapol, 0.1%-1%, PVP K30,0.2%-1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210259749.9A CN103565740A (en) | 2012-07-25 | 2012-07-25 | Loteprednol etabonate suspension eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210259749.9A CN103565740A (en) | 2012-07-25 | 2012-07-25 | Loteprednol etabonate suspension eye drops |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103565740A true CN103565740A (en) | 2014-02-12 |
Family
ID=50039023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210259749.9A Pending CN103565740A (en) | 2012-07-25 | 2012-07-25 | Loteprednol etabonate suspension eye drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103565740A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265502A (en) * | 2015-05-27 | 2017-01-04 | 天津金耀集团有限公司 | A kind of stable Loteprednol etabonate suspension eye drop composition |
| CN106902079A (en) * | 2015-12-21 | 2017-06-30 | 天津金耀集团有限公司 | A kind of Loteprednol etabonate suspension eye drop composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| CN101152191A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Lotepredenol etabonate gernebcin suspension solution and method for preparing the same |
| CN101849910A (en) * | 2010-05-18 | 2010-10-06 | 重庆华邦制药股份有限公司 | Preparation method of betamethasone dipropionate micro-particle |
-
2012
- 2012-07-25 CN CN201210259749.9A patent/CN103565740A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| CN101152191A (en) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | Lotepredenol etabonate gernebcin suspension solution and method for preparing the same |
| CN101849910A (en) * | 2010-05-18 | 2010-10-06 | 重庆华邦制药股份有限公司 | Preparation method of betamethasone dipropionate micro-particle |
Non-Patent Citations (4)
| Title |
|---|
| DR.ADRIAN HILL等: "流变特性与颗粒参数的关系研究", 《实验与分析》 * |
| 朱万章: "固体离子对浓悬浮液流行性能的影响", 《应用科学学报》 * |
| 罗杰英等: "《现代物理药剂学理论与实践》", 30 April 2005 * |
| 郝吉明等: "《大气污染控制工程》", 31 January 2010 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265502A (en) * | 2015-05-27 | 2017-01-04 | 天津金耀集团有限公司 | A kind of stable Loteprednol etabonate suspension eye drop composition |
| CN106902079A (en) * | 2015-12-21 | 2017-06-30 | 天津金耀集团有限公司 | A kind of Loteprednol etabonate suspension eye drop composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103565737A (en) | Compound glucocorticoid eye drops | |
| CN103565738A (en) | Rapidly-dispersed water-mixed suspension medicine used for eyes | |
| US9241876B2 (en) | Aripiprazole medicament formulation and preparation method therefor | |
| CN112138250B (en) | Medicament fluid dispenser and dexmedetomidine nasal spray device for maintaining uniform administration | |
| EP2806872A1 (en) | Bendamustine compositions and methods therefore | |
| CN106924172B (en) | Huperzine A lyotropic liquid crystal preparation and preparation method thereof | |
| Dholakia et al. | Development and characterisation of thermo reversible mucoadhesive moxifloxacin hydrochloride in situ ophthalmic gel | |
| CN103565741A (en) | Glucocorticoid ophthalmic water suspension having redispersibility | |
| CN103565742A (en) | Fluorometholone eye drops | |
| CN104523587A (en) | Bromfenac sodium eye drops and preparation method thereof | |
| WO2013165130A1 (en) | Stabilized liquid preparation for injection containing pemetrexed | |
| CN103565740A (en) | Loteprednol etabonate suspension eye drops | |
| CN105412003A (en) | Besifloxacin hydrochloride eye drops and preparation method thereof | |
| CN100381116C (en) | Quisnon dispersion tablet | |
| CN103565816A (en) | Tobramycin-dexamethasone eye drops | |
| CN101669901A (en) | Liquid preparation for dosing eyes and method for making the same | |
| CN103565739A (en) | Rimexolone eye drops | |
| CN102342910B (en) | Levofloxacin hydrochloride injection pharmaceutical composition and preparation method thereof | |
| CN102824345A (en) | Irinotecan hydrochloride composition and preparation method thereof | |
| TW201632188A (en) | Formulation | |
| CA3160484A1 (en) | Ophthalmic pharmaceutical compositions | |
| US10463674B2 (en) | Process for manufacturing sterile ophthalmic pharmaceutical suspensions | |
| CN102636600A (en) | Method for determination of optical isomers in palonosetron hydrochloride composition | |
| CN117120048A (en) | Suspension containing heterocyclylene acetamide derivative | |
| CN103919780B (en) | Calming soporific preparation, its compound preparation, preparation method and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140212 Assignee: Tianjin Pharmaceutical Industry Group Corp., Ltd. Assignor: Tianjin Jinyao Group Co., Ltd. Contract record no.: 2015120000054 Denomination of invention: Loteprednol etabonate suspension eye drops License type: Common License Record date: 20150916 Application publication date: 20140212 Assignee: Pharmaceutical Co., Ltd. Tianjin Jin Yao Assignor: Tianjin Pharmaceutical Industry Group Corp., Ltd. Contract record no.: 2015120000076 Denomination of invention: Loteprednol etabonate suspension eye drops License type: Fen Xuke Record date: 20150929 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140212 |